2e:I[856015,["/_next/static/immutable/chunks/1xzisbplk9czp.js","/_next/static/immutable/chunks/3j2i1faptc_-9.js","/_next/static/immutable/chunks/0gcbsntq5_9qd.js","/_next/static/immutable/chunks/08tq8rmv423j5.js","/_next/static/immutable/chunks/3o-s-fbpanizg.js","/_next/static/immutable/chunks/0-t9leoxnnuho.js","/_next/static/immutable/chunks/311zvdjfxff-f.js","/_next/static/immutable/chunks/1a_hqhrsle_n_.js"],"default"] 2f:T64dd,

CATEGORY	DETAIL
Risk Factors	Adults aged 40 to 60, family history, autoimmune comorbidities, prior viral infection, history of allergies, elevated sodium intake
Etiology	Idiopathic endolymphatic hydrops; proposed mechanisms include impaired endolymph reabsorption, autoimmune inner ear damage, viral injury to the endolymphatic sac
Patient Presentation	Recurrent episodes of severe rotatory vertigo lasting 20 minutes to several hours, accompanied by unilateral fluctuating hearing loss, low-pitched roaring tinnitus, and aural fullness
Classic Physical Exam	Horizontal nystagmus during acute attack (initially toward, then away from the affected ear); Weber lateralizes to the unaffected ear; Rinne positive bilaterally (air conduction > bone conduction, consistent with sensorineural pattern); exam may be entirely normal between attacks
Key Diagnostic Results	Audiometry showing low-frequency sensorineural hearing loss; electrocochleography with elevated $SP/AP$ ratio; MRI of the internal auditory canal to exclude vestibular schwannoma
Management	Acute: meclizine or dimenhydrinate for vestibular suppression, antiemetics. Chronic: dietary sodium restriction, thiazide diuretics, betahistine. Refractory: intratympanic gentamicin or dexamethasone, surgical decompression of the endolymphatic sac
Keywords	"Episodic vertigo with hearing loss," "low-frequency sensorineural hearing loss," "aural fullness," "roaring tinnitus," "endolymphatic hydrops," "vertigo lasting 20 minutes to hours"

1. Pathophysiology

Meniere's disease is fundamentally a disorder of endolymph volume regulation within the membranous labyrinth of the inner ear. The pathological hallmark is endolymphatic hydrops, which refers to abnormal distension of the endolymph-containing spaces (the cochlear duct, saccule, and utricle). This distension occurs because of either overproduction of endolymph or, more likely, impaired reabsorption by the endolymphatic sac.

The endolymph is a unique extracellular fluid with an ionic composition resembling intracellular fluid: it is high in potassium ($K^+$ approximately 150 mEq/L) and low in sodium. In contrast, the perilymph surrounding the membranous labyrinth is high in sodium and low in potassium, similar to typical extracellular fluid. When endolymphatic pressure rises, the Reissner membrane (the thin membrane separating the scala media from the scala vestibuli) becomes progressively stretched. Eventually, it ruptures.

This rupture is the critical event that triggers an acute attack. When the membrane breaks, potassium-rich endolymph floods into the perilymphatic space, bathing the vestibular nerve fibers and hair cells in a toxic concentration of potassium. This causes sustained depolarization and then paralysis of the sensory neurons on the affected side. The brain interprets this sudden asymmetry in vestibular input as violent motion, producing severe rotatory vertigo. At the same time, potassium toxicity to the cochlear hair cells causes the acute hearing loss and intensification of tinnitus during the attack.

After the membrane heals and potassium is cleared, symptoms improve. However, each cycle of distension, rupture, and healing damages hair cells incrementally. This explains the natural history of the disease: early on, hearing returns to baseline between attacks (fluctuating loss), but over years, permanent sensorineural hearing loss develops as cumulative hair cell destruction becomes irreversible.

The low-frequency hearing loss seen early in the disease is explained by the anatomy of the cochlear apex. The apical turn, which processes low-frequency sounds, is the region most susceptible to hydrops-related distortion because the basilar membrane is widest and most compliant there. As the disease advances, the hearing loss extends to involve middle and eventually high frequencies.

The sensation of aural fullness correlates directly with increased endolymphatic pressure, functioning essentially as the ear's equivalent of a pressure sensation. The tinnitus is thought to result from spontaneous depolarization of damaged cochlear hair cells generating aberrant signals perceived as sound.

2. Classification and Clinical Manifestation

The diagnostic criteria for Meniere's disease distinguish between two levels of certainty:

CLASSIFICATION	CRITERIA
Definite Meniere's Disease	Two or more spontaneous episodes of vertigo, each lasting 20 minutes to 12 hours; audiometrically documented low- to mid-frequency sensorineural hearing loss in the affected ear on at least one occasion before, during, or after a vertigo episode; fluctuating aural symptoms (hearing loss, tinnitus, or fullness) in the affected ear; not better accounted for by another vestibular diagnosis
Probable Meniere's Disease	Two or more episodes of vertigo or dizziness, each lasting 20 minutes to 24 hours; fluctuating aural symptoms (hearing, tinnitus, or fullness) in the affected ear; not better accounted for by another vestibular diagnosis

The clinical course can also be described by staging, which reflects the progression of hearing loss over time:

STAGE	HEARING LOSS PATTERN	CLINICAL FEATURES
Stage 1 (Early)	Low-frequency sensorineural hearing loss that fluctuates and recovers between episodes	Episodic vertigo with full return to baseline hearing; aural fullness and tinnitus present mainly during or around attacks
Stage 2 (Intermediate)	Fluctuating hearing loss across low and mid frequencies with incomplete recovery	Attacks may become less violent, but hearing progressively worsens; tinnitus becomes more constant
Stage 3 (Late)	Fixed, flat sensorineural hearing loss across all frequencies	Vertigo episodes may decrease ("burned-out" phase), but chronic imbalance and permanent hearing loss persist; tinnitus is constant
Stage 4 (Bilateral)	Involvement of the contralateral ear (occurs in approximately 25 to 40% of patients over 10 to 20 years)	Bilateral fluctuating hearing loss; bilateral tinnitus; significantly impaired quality of life

3. Diagnostic Workup

TEST	PURPOSE	KEY FINDINGS
Pure Tone Audiometry	Best initial test; documents hearing loss pattern	Low-frequency sensorineural hearing loss (rising audiogram pattern); fluctuates between episodes early in the disease
Electrocochleography (ECoG)	Confirms endolymphatic hydrops	Elevated summating potential to action potential ratio ($SP/AP > 0.40$); supports diagnosis when clinical criteria are ambiguous
MRI with Gadolinium	Excludes retrocochlear pathology	Rules out vestibular schwannoma (acoustic neuroma); may also show endolymphatic hydrops on dedicated sequences
Caloric Testing (VNG)	Assesses vestibular function asymmetry	Reduced or absent caloric response (canal paresis) on the affected side
Glycerol or Furosemide Dehydration Test	Provocative test rarely used	Transient hearing improvement after osmotic dehydration supports endolymphatic hydrops

Audiometry is the starting point whenever you suspect Meniere's disease. The classic finding is a low-frequency sensorineural hearing loss with a "rising" audiogram, meaning thresholds are worst at 250 and 500 Hz and improve at higher frequencies. This pattern is the opposite of presbycusis (age-related hearing loss), which affects high frequencies first, and that contrast is a commonly tested discriminator. On repeat testing between attacks, the hearing may return to normal early in the disease course, confirming the fluctuating nature.

After audiometric confirmation, the next step is to order an MRI of the internal auditory canals with gadolinium enhancement. The primary reason is not to confirm Meniere's disease but to exclude a vestibular schwannoma, which can mimic the presentation with progressive unilateral sensorineural hearing loss and tinnitus. A normal MRI effectively rules out this dangerous mimic. Some newer MRI protocols (3T MRI with delayed gadolinium) can directly visualize endolymphatic hydrops, though this is not yet the standard of care.

Electrocochleography is a valuable adjunctive test. It measures the electrical potentials generated by the cochlea and auditory nerve in response to sound. In endolymphatic hydrops, the summating potential (generated by hair cell displacement on the distended basilar membrane) is disproportionately elevated relative to the action potential, producing an elevated $SP/AP$ ratio (greater than 0.40). This test is helpful when the clinical picture is uncertain or when audiometric results are equivocal.

Caloric testing as part of videonystagmography assesses the function of each horizontal semicircular canal independently by irrigating the ear with warm and cool water or air. In Meniere's disease, you typically find a reduced vestibular response on the affected side, reflecting damage to the vestibular end-organ. This finding is supportive but not confirmatory, as many vestibular disorders cause canal paresis.

The diagnosis of Meniere's disease remains primarily clinical. No single laboratory or imaging test is the gold standard. The diagnosis is established when a patient meets the published criteria (episodic vertigo of appropriate duration, documented hearing loss, fluctuating aural symptoms) and other causes have been excluded.

4. Management and Treatment

PHASE	INTERVENTION	DETAILS
Acute Attack	Vestibular suppressants	Meclizine 25 mg every 6 to 8 hours as needed; dimenhydrinate 50 mg every 6 hours
Acute Attack	Antiemetics	Promethazine 25 mg PO/PR every 6 hours or ondansetron 4 to 8 mg PO/IV every 8 hours
Acute Attack	Benzodiazepines (severe attacks)	Diazepam 2 to 5 mg PO/IV as needed for refractory vertigo
Chronic Prophylaxis	Dietary modification	Sodium restriction to less than 1500 to 2000 mg per day; limit caffeine and alcohol; adequate hydration
Chronic Prophylaxis	Diuretics	Hydrochlorothiazide 25 to 50 mg daily or acetazolamide 250 mg twice daily to reduce endolymph volume
Chronic Prophylaxis	Betahistine	16 to 48 mg daily in divided doses (widely used outside the United States)
Refractory Disease	Intratympanic corticosteroids	Dexamethasone 4 mg/mL injected through the tympanic membrane; preserves hearing; first-line salvage therapy
Refractory Disease	Intratympanic gentamicin	Chemical ablation of vestibular function; highly effective for vertigo control but carries a 20 to 30% risk of further hearing loss
Refractory Disease	Endolymphatic sac surgery	Decompression or shunting of the endolymphatic sac; hearing-preserving surgical option
Last Resort	Vestibular nerve section	Eliminates vertigo while preserving hearing; requires craniotomy
Last Resort	Labyrinthectomy	Complete surgical destruction of the labyrinth; eliminates vertigo but causes total hearing loss in the affected ear; reserved for patients with non-serviceable hearing

Acute management focuses on symptom control during an attack. The first-line agents are vestibular suppressants such as meclizine (an antihistamine) or dimenhydrinate, which reduce the intensity of vertigo by dampening vestibular nerve activity. Promethazine or ondansetron controls the nausea and vomiting that accompany severe attacks. In the emergency setting, intravenous diazepam may be used for attacks that do not respond to first-line agents. Importantly, vestibular suppressants should not be used as chronic daily medication because they impair central vestibular compensation, which the brain needs to adapt to progressive vestibular damage.

Long-term prophylactic management begins with lifestyle modification. Sodium restriction (below 1500 to 2000 mg per day) is the cornerstone of chronic management and is the most commonly tested initial step for long-term control. The rationale is that reduced sodium intake decreases fluid retention, lowering endolymphatic pressure. Patients are also advised to avoid caffeine, alcohol, and nicotine, all of which can exacerbate symptoms. If dietary changes alone are insufficient, a thiazide diuretic such as hydrochlorothiazide is added to further reduce endolymph volume. Betahistine, a histamine analogue that improves blood flow to the stria vascularis, is used widely in Europe and Asia and has evidence supporting attack reduction, though it is not FDA-approved in the United States.

For patients with refractory disease (continued disabling vertigo despite medical therapy), the next best step is intratympanic dexamethasone injection. This delivers a high concentration of corticosteroid directly to the inner ear through the round window membrane, with the advantage of preserving hearing. If corticosteroid injections fail, intratympanic gentamicin is an effective option. Gentamicin is an aminoglycoside antibiotic that is selectively vestibulotoxic, meaning it destroys vestibular hair cells while relatively sparing cochlear hair cells. This "chemical labyrinthectomy" controls vertigo in over 80% of patients but carries a meaningful risk (20 to 30%) of worsening hearing loss.

Surgical options are reserved for patients who have failed all medical and intratympanic therapies. Endolymphatic sac decompression is a hearing-preserving procedure that aims to improve drainage of endolymph. Vestibular nerve section (selective transection of the vestibular portion of cranial nerve VIII) eliminates vertigo while maintaining hearing but requires a craniotomy. Labyrinthectomy is the definitive procedure for vertigo elimination but completely destroys hearing in the operated ear, making it appropriate only for patients whose hearing is already non-functional.

Vestibular rehabilitation therapy is an essential adjunct at all stages. After each acute episode, guided exercises help the brain compensate for vestibular asymmetry and reduce chronic imbalance.

5. Differential Diagnosis and Distractors

DIFFERENTIAL	WHY IT IS SIMILAR	KEY DISCRIMINATOR
Benign Paroxysmal Positional Vertigo (BPPV)	Episodic vertigo in a middle-aged adult	BPPV episodes last seconds to under one minute, are triggered by head position changes, and produce a positive Dix-Hallpike test; there is no hearing loss, tinnitus, or aural fullness
Vestibular Neuritis	Acute severe vertigo with nausea	Vestibular neuritis causes a single prolonged episode lasting days (not recurrent), often post-viral; critically, there is no hearing loss because only the vestibular nerve is affected
Labyrinthitis	Acute vertigo with concurrent sensorineural hearing loss	Labyrinthitis presents as a single episode (not recurrent) of vertigo with hearing loss, usually following an upper respiratory infection; Meniere's disease is defined by recurrent episodes
Vestibular Schwannoma (Acoustic Neuroma)	Unilateral sensorineural hearing loss with tinnitus	Vestibular schwannoma causes gradually progressive hearing loss (not episodic or fluctuating); vertigo is uncommon; MRI shows an enhancing mass at the cerebellopontine angle
Vestibular Migraine	Recurrent episodic vertigo in a patient with headache history	Vertigo episodes in vestibular migraine are often accompanied by photophobia, phonophobia, or visual aura; audiometry is normal between and during attacks; no progressive hearing loss
Perilymphatic Fistula	Vertigo with sensorineural hearing loss	History of preceding trauma, barotrauma, or straining; positive fistula test (vertigo/nystagmus with pneumatic otoscopy or Valsalva); onset is acute, not recurrent over years
Superior Semicircular Canal Dehiscence	Vertigo triggered by sound or pressure, with conductive hearing component	Vertigo induced by loud sounds (Tullio phenomenon) or pressure changes; CT temporal bone reveals bony dehiscence of the superior canal; air-bone gap on audiometry mimics conductive loss

6. Traps and High-Yield Pearls

The most common way students get questions about Meniere's disease wrong is by confusing the duration of vertigo episodes with those of other vestibular disorders. This is the single most reliable discriminator on exam vignettes. Vertigo lasting seconds points to BPPV. Vertigo lasting 20 minutes to several hours with associated hearing loss and tinnitus points to Meniere's disease. Vertigo lasting days in a single prolonged episode points to vestibular neuritis (without hearing loss) or labyrinthitis (with hearing loss). If the vignette describes a patient with recurrent vertigo and you see the phrase "lasting hours" combined with "low-pitched roaring tinnitus" or "ear fullness," that is Meniere's disease until proven otherwise.

A second common trap involves the pattern of hearing loss. Students who see "sensorineural hearing loss" may reflexively think of presbycusis, but the key detail is frequency distribution. Meniere's disease preferentially affects low frequencies early on, producing a rising audiogram. Presbycusis and noise-induced hearing loss affect high frequencies. This detail is often embedded in the answer choices as an audiogram image, and selecting the wrong pattern is a frequent error.

Another pitfall is the management sequence. When a vignette describes a patient with known Meniere's disease whose attacks are not controlled by sodium restriction and diuretics, the next best step is intratympanic dexamethasone, not gentamicin. Corticosteroids are tried first because they preserve hearing. Gentamicin is reserved for cases that fail steroid injections, because it carries a real risk of permanent hearing loss. Jumping straight to gentamicin or surgery without first trying intratympanic corticosteroids is a common sequencing error.

Finally, always remember to order an MRI when a patient presents with unilateral sensorineural hearing loss and tinnitus. Even if the clinical picture fits Meniere's disease perfectly, the vignette may be testing whether you recognize the need to exclude a vestibular schwannoma before finalizing the diagnosis. The core competency being tested with Meniere's disease is your ability to distinguish episodic vestibular syndromes by duration and associated symptoms, sequence the diagnostic workup appropriately, and escalate management in a stepwise fashion from conservative to interventional.

1f:["$","$L2e",null,{"article":{"id":"6013e751-bf63-41ec-82e5-96bbdd32042d","title":"Penyakit Meniere/ Meniere's Disease","content":"$2f","category":"Neurologi","created_at":"2026-09-03T17:05:34.673346+00:00","status":"published","subcategory":null},"questionCount":0,"sections":[{"id":"section-pathophysiology","num":"01","title":"Pathophysiology"},{"id":"section-classification-and-clinical-manifestation","num":"02","title":"Classification and Clinical Manifestation"},{"id":"section-diagnostic-workup","num":"03","title":"Diagnostic Workup"},{"id":"section-management-and-treatment","num":"04","title":"Management and Treatment"},{"id":"section-differential-diagnosis-and-distractors","num":"05","title":"Differential Diagnosis and Distractors"},{"id":"section-traps-and-high-yield-pearls","num":"06","title":"Traps and High-Yield Pearls"}],"hasSummaryTable":true}]